How SUPPORT Will Affect Pharma Interactions With DEA
The opioid package President Donald Trump signed last week garnered much attention. While it is largely directed at treatment and prevention, it contains several momentous provisions for those companies that manufacture,...To view the full article, register now.
Already a subscriber? Click here to view full article